ACADIA Pharmaceuticals Awarded New Grant from The Michael J. Fox Foundation for Development of Nurr1-RXR Selective Agonists to Treat Parkinson's Disease

ACADIA Pharmaceuticals Inc.

today announced that it has been awarded a new grant from The Michael J. Fox Foundation (MJFF) for the further development of Nurr1-RXR selective agonists for the treatment of Parkinson's disease. The grant of $322,000 is a supplemental award to expand on promising initial research conducted by ACADIA under an earlier grant from MJFF. The initial grant was made under the Foundation's Therapeutics Development Initiative (

) aimed at supporting preclinical development of Parkinson's disease therapies that have the potential for fundamentally altering disease course and improving treatment of symptoms above and beyond current standards of care. The new grant has been awarded to expand upon the work originally awarded through the TDI program. “Our Foundation is devoted to finding a disease-modifying treatment to halt the progression of Parkinson's, the major unmet need for those living with the disease today,” said Jamie Eberling, Ph.D., associate director of research programs at MJFF. “Data from ACADIA's initial experiments targeting Nurr1 have been encouraging to this end.”